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CC BY liceAvailable online xxxBackground: Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination
with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of ‘platinum-
sensitive’ ovarian cancer and has been shown to improve progression-free survival (PFS).
Patients and methods: ICON6 (NCT00532194) was an international three-arm, double-blind, placebo-controlled
randomised trial. Between December 2007 and December 2011, 456 women were randomised, using stratification,
to receive either chemotherapy with placebo throughout (arm A, reference); chemotherapy with concurrent
cediranib, followed by maintenance placebo (arm B, concurrent); or chemotherapy with concurrent cediranib,
followed by maintenance cediranib (arm C, maintenance). Due to an enforced redesign of the trial in September
2011, the primary endpoint became PFS between arms A and C which we have previously published, and the
overall survival (OS) was defined as a secondary endpoint, which is reported here.
Results: After a median follow-up of 25.6 months, strong evidence of an effect of concurrent plus maintenance
cediranib on PFS was observed [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.44-0.72, P < 0.0001]. In this
final update of the survival analysis, 90% of patients have died. There was a 7.4-month difference in median
survival and an HR of 0.86 (95% CI: 0.67-1.11, P ¼ 0.24) in favour of arm C. There was strong evidence of a
departure from the assumption of non-proportionality using the GrambscheTherneau test (P ¼ 0.0031), making the
HR difficult to interpret. Consequently, the restricted mean survival time (RMST) was used and the estimated
difference over 6 years by the RMST was 4.8 months (95% CI: 0.09 to 9.74 months).
Conclusions: Although a statistically significant difference in time to progression was seen, the enforced curtailment in
recruitment meant that the secondary analysis of OS was underpowered. The relative reduction in the risk of death of
14% risk of death was not conventionally statistically significant, but this improvement and the increase in the mean
survival time in this analysis suggest that cediranib may have worthwhile activity in the treatment of recurrent
ovarian cancer and that further research should be undertaken.
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Ovarian cancer is the leading cause of death from gynae-
cological tumours in high-income countries. Most women
present with advanced disease and in more than 75% of
these patients the disease recurs after frontline treatment.
Many have disease that will respond again to treatment,
usually with platinum-based chemotherapy, but the
response duration becomes shorter with each subsequent
therapy, and the disease in these patients is almost
invariably fatal.1 Combining chemotherapies with targeted
ESMO Open J. A. Ledermann et al.therapies to enhance their effect and/or using such drugs
as maintenance therapy to improve the effectiveness of
treatment by lengthening the time to disease progression
and subsequent treatment, and ultimately improving sur-
vival, is a major research strategy in ovarian cancer. One
approach is to inhibit angiogenesis, the process of new
blood vessel formation, which is required for tumour
growth.2 This has been validated through randomised
phase III trials using the monoclonal anti-vascular endo-
thelial growth factor (VEGF) antibody, bevacizumab, which
increases the response rate to chemotherapy3-5 and ex-
tends progression-free survival (PFS).3-7
Cediranib (AZD2171) is an oral VEGF receptor (VEGFR 1-3)
and c-Kit8 inhibitor that has shown antitumor activity in
recurrent ovarian, colorectal, advanced biliary tract, renal
and lung cancers, glioblastoma and alveolar soft-part sar-
coma.9-15 On the basis of phase II activity in ovarian cancer9
we investigated the potential benefit obtained by admin-
istering cediranib together with chemotherapy and as
maintenance therapy in patients with ‘platinum-sensitive’
ovarian cancer who had had radiological evidence of
recurrence more than 6 months after completion of
first-line chemotherapy.16 The ICON (International
Collaboration for Ovarian Neoplasia) 6 trial was an
investigator-initiated, academically-led trial (NCT00532194)
developed through the GCIG (Gynecologic Cancer Inter-
Group), and led by the MRC Clinical Trials Unit at University
College London (UCL).
The ICON6 trial opened in December 2007. In October
2011, when 380 patients had been randomised,
AstraZeneca announced a cessation in the manufacture of
cediranib due to disappointing results from trials in colo-
rectal cancer, non-small-cell lung carcinoma and glioblas-
toma.13,17,18 Due to a limited drug supply the original plan
to recruit 2000 patients had to be modified and reduced to
440 patients on the 20 mg dose. In order to recapture as
much statistical power as possible, the primary endpoint
was changed from OS to PFS. These changes were all made
blind to any accumulating data from ICON6 itself. In 2016
the primary trial outcome measure was reported, demon-
strating a median PFS of 11.0 months with concurrent plus
maintenance cediranib in comparison to 8.7 months in the
placebo arm (HR 0$56, 0.44-0.72, P < 0.0001). Here we
report the overall survival (OS) after extended follow-up and
exploratory endpoints. Thirty patients were treated at the
higher 30 mg dose, but the primary analysis and this OS
update focus on the 20 mg dose.19
PATIENTS AND METHODS
Participants and trial design
Women from 62 centres in the UK, Canada, Australia, New
Zealand and Spain with recurrent ovarian, fallopian tube or
primary peritoneal cancer requiring further platinum-based
chemotherapy 6 months after completing first-line
chemotherapy were entered into ICON6. The inclusion
and exclusion criteria have been previously described.16
Patients, using permuted blocks (alternating between 8and 16) and stratified for GCIG group, first-line chemo-
therapy including paclitaxel, relapse-free interval (6-12/>12
months), planned chemotherapy regimen and previous
bevacizumab treatment were randomised to one of three
treatment arms in a 2 : 3 : 3 ratio. Arm A (reference)
received chemotherapy plus daily oral placebo tablets
throughout chemotherapy and continued as maintenance,
arm B (concurrent) received daily oral cediranib during
chemotherapy then switched to placebo during mainte-
nance and arm C (concurrent þ maintenance) received
cediranib during chemotherapy and continued cediranib as
maintenance. See Figure 1 for CONSORT diagram.
Treatment
Six cycles of three-weekly chemotherapy were planned, but
the maintenance phase could begin after a minimum of four
cycles if patients were unable to complete six cycles. Car-
boplatin with either paclitaxel or gemcitabine was the rec-
ommended treatment but carboplatin monotherapy or
cisplatin, if combination regimens could not be given, were
allowed.20,21 Protocol-defined dose reductions of chemo-
therapy were carried out if necessary.
Trial drug, cediranib or placebo, was started with
chemotherapy and continued to progression or unaccept-
able toxicity. An initial safety phase employed a single daily
dose of 30 mg. Following review of the first 30 patients in
November 2008,19 the Independent Data Monitoring
Committee recommended reducing the dose of cediranib
from 30 mg to 20 mg, in line with ongoing combination
phase III trials.10,22,23 Clinicians were provided with clinical
guidelines to aid early management of the main toxicities of
cediranib which were hypertension, diarrhoea, proteinuria
and fatigue. Toxicity-related interruption of trial drug for up
to 2 weeks was permitted to allow recovery to grade 1. A
dose reduction to 15 mg was permitted and required for
grade 3 toxicity. Cediranib/placebo was discontinued
permanently if gastrointestinal perforation, arterial throm-
boembolic event, grade 4 haemorrhage, hypertensive crisis
or reversible posterior leukoencephalopathy syndrome
(RPLS) occurred.
Statistical analysis
The revised sample size, fully described in the original
publication, required 440 patients to be randomised to the
20 mg dose. In order to maximise the limited power, the
primary comparison was revised from the two pairwise
arm A versus arm B versus arm C comparisons to a single
pairwise arm A versus arm C comparison. This decision
was taken as it was considered the most appropriate
comparison to target given the emerging data for con-
current and maintenance bevacizumab.3,4,6 The changes
of primary outcome and sample size were made before
any interim analysis was carried out of efficacy outcome
measures. After 176 events there would be least 80%
power to detect a PFS hazard ratio (HR) of 0.65 with a 5%
two-sided significance level. This is detailed further in the
Statistical Analysis Plan (Supplementary Material,
62 sites from 4 GCIG groups enrolled 
women in the ICON6 trial (n= 486)
Randomised to 20 mg dose (n= 456)
Ratio of 2:3:3
Cediranib during chemotherapy 
and maintenance placebo
Randomised to arm B (n= 174)
Ineligible (n= 1)
 Poor renal function (n= 1)
Cediranib during chemotherapy 
and maintenance cediranib
Randomised to arm C (n= 164)
Ineligible (n= 4)
 ECOG status not 0-1 (n= 1)
 Poor renal function (n= 1)
 <2 week washout (n= 2)
 CT scan out of date (n= 1)
Placebo during chemotherapy 
and maintenance placebo
Randomised to arm A (n= 118)
Ineligible (n= 1)
 ECOG status not 0-1 and 
poor renal function (n= 1)
Started maintenance phase 
(n= 85)
Started maintenance phase 
(n= 113)
Started maintenance phase 
(n= 95)
Randomised to initial 30 mg dose (n= 30)
Excluded; stopped because of increased toxicity
Analysed (n= 118)
Status at data cut off
 Alive, without progression 
(n= 3)
 Alive, with progression  
(n= 9)
 Dead, without progression 
(n= 3)
 Dead, with progression 
(n= 103)
Ongoing on trial drug (n= 0)
Lost to follow up (n= 0)
Analysed (n= 174)
Status at data cut off
 Alive, without progression 
(n= 6)
 Alive, with progression 
(n= 12)
 Dead, without progression 
(n= 6)
 Dead, with progression 
(n= 150)
Ongoing on trial drug (n= 0)
Lost to follow up (n= 0)
Analysed (n= 164)
Status at data cut off
 Alive, without progression 
(n= 6)
 Alive, with progression  
(n= 9)
 Dead, without progression 
(n= 3)
 Dead, with progression 
(n= 146)
Ongoing on trial drug (n= 0)
Lost to follow up (n= 0)
Started chemotherapy phase 
(n= 118)
 Completed at least one cycle 
of chemotherapy (n= 117)
 Completed six cycles of 
chemotherapy (n= 93)
 SAE deaths (n= 1)
Received trial drug (n= 115)
Started chemotherapy phase 
(n= 174)
 Completed at least one cycle 
of chemotherapy (n= 174) 
 Completed six cycles of 
chemotherapy (n= 142)
 SAE deaths (n= 2)
Received trial drug (n= 171)
Started chemotherapy phase 
(n= 164)
 Completed at least one cycle 
of chemotherapy (n= 164) 
 Completed six cycles of 
chemotherapy (n= 130)
 SAE deaths (n= 1)
Received trial drug (n= 158)
Figure 1. CONSORT diagram.
ECOG, Eastern Cooperative Oncology Group; GCIG, Gynecologic Cancer InterGroup; SAE, serious adverse events.
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00043) and the protocol is available at http://www.
icon6.org/protocol.
At the time of the primary outcome reported in the
Lancet by Ledermann et al.16, an immature analysis of OS
was presented. This analysis was after 52% of patients had
died and stated that OS “will be assessed again when more
than 80% of deaths have occurred”. In order to maximise the
limited power available, we delayed the ultimate OS analysis
until now. Late in 2014, when 74% of patients had died, an
unplanned analysis was carried out by AstraZeneca as part
of their submission of the data to the European Medicines
Agency (EMA). This analysis was eventually published online
by the EMA on 21 December 2016 and “suggested a benefit
in OS for [arm C] (median OS 27.9 months) compared with
[arm A] (median 19.9 months). Nevertheless, this improve-
ment was not conventionally statistically significant”.24 The
analysis presented here was carried out with 90% of deaths
having occurred in the two primary comparison arms
The revised Statistical Analysis Plan did not specify when
the secondary outcome measure of OS would be analysed.
However, given the reduced power, the analysis was
delayed until fewer than 10% of patients were still alive.
Following the reporting of the primary endpoint, the log-
rank (LR) test was used as the primary test of an overall
difference between KaplaneMeier curves. A pre-specified
plan to address the proportionality of hazards was made,
due to the difficulty of interpreting the HR in the presence
of time-dependent treatment effects. The presence of non-
proportional hazards was to be assessed using the
GrambscheTherneau test.25 If there were evidence of non-
proportionality at the 5% level, survival data would be
modelled by a flexible parametric model and differences in
restricted mean survival time (RMST) would be estimated,
otherwise a standard Cox model would be used.26 Without
evidence of non-proportional hazards and given the pres-
ence of non-proportional hazards in the primary endpoint
of PFS, and the corresponding reduction in power when the
LR test is used in its presence, further statistical methods
were sought that would protect the (already severely
reduced) power available to detect a difference in OS. The
decision was made to utilise the RoystoneParmar com-
bined test as well as the LR test.27 In a reconstruction of 50
published trials, the combined test outperformed the Cox
test overall.28 This was implemented in Stata 15.1.29 OS was
defined as time from randomisation to date of death from
any cause. Patients who were still alive at the time of
analysis were censored at the date last known to be alive.
In addition, the time to first subsequent treatment (TFST)
was measured as an exploratory outcome given its emerging
clinical relevance and the fact that patients could continue
trial drug beyond documented disease progression.
RESULTS
Overall survival
As reported previously, all three treatment groups were
balanced with respect to their pre-treatment demographiccharacteristics.16 The 456 women receiving cediranib 20
mg/placebo had a median age of 62 years and were rand-
omised at a median of 19.6 months from first diagnosis. No
patients were lost to follow-up; five withdrew consent for
collection of further data.
Median follow-up, using the inverse KaplaneMeier
method, was 7 years at 83.7 months in arms A and C
with a database cut-off date of 1 October 2018. At this
point 106/118 (90%) deaths in arm A and 149/164 (91%) in
arm C had occurred. The median survival in arm A was 19.9
months [95% confidence interval (CI): 17.4-26.5] and in arm
C 27.3 months (24.8-33.0), a difference of 7.4 months. The
HR estimate was 0.86 with a 95% CI of 0.67-1.11. The sur-
vival differences in the KaplaneMeier plot (Figure 2) appear
to show a separation until around 30 months. Using the LR
test, the difference in survival was not conventionally
statistically significant (P ¼ 0.24), but there was strong
evidence of a departure from the assumption of non-
proportionality using the GrambscheTherneau test, P ¼
0.0031.25 Consequently, we calculated the RMST as a
measure of the difference in OS. Concurrent and mainte-
nance treatment with cediranib (arm C) was associated with
increased time until death over a period of 6 years by a
mean of 4.8 (95% CI: 0.09 to 9.74) months over the
reference (arm A), from 29.5 to 34.3 months. A similar
number of deaths occurred (90%:156/174) in arm B (con-
current treatment) and the median survival time was closer
to the concurrent þ maintenance arm (arm C) at 26.6
months (RMST 32.0 months), again consistent with the
suggested positive effect of cediranib (Figure 2). Results for
all 486 patients randomised, including those on the 30 mg
dose, are consistent with this result and are included in
the Supplementary Material, available at https://doi.
org/10.1016/j.esmoop.2020.100043.
Cediranib as a maintenance treatment prolonged the
median TFST compared with placebo with a difference in
RMST of 5.2 months from 13.2 to 18.5 months. An HR of
0.64 (0.49-0.85) was observed, illustrating that patients on
cediranib were delayed going onto a subsequent treatment,
LR P value ¼ 0.0014 (Figure 3). Cediranib during chemo-
therapy alone (arm B) did not lengthen TFST, with a median
interval of 11.7 months.Toxicity
No additional toxicity has been reported since the detailed
primary results of the primary outcome, reported in 2016.
The median time on trial drug for arm A was 8.2 months
and arm C, 7.6 months. A significant number of patients
continued on trial drug beyond 12 months, noticeably in the
maintenance arm compared with placebo (26% versus 19%)
and this difference persisted at 18 months (11% versus 5%).
One patient on the maintenance arm continued cediranib
treatment for 5.4 years before developing progressive dis-
ease. Three patients (2.5%) on arm A and six patients (3.7%)
on arm C never started any trial treatment.
In those patients who received trial drug for at least 12
months [22 (19%) in arm A and 42 (26%) in arm C], and
Log-rank test P = 0.24
Grambsch–Therneau test P = 0.0031
4.8 month RMST increase over placebo (29.5 to 34.3 months)
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Figure 2. Overall survival.
KaplaneMeier plot of overall survival: (a) Arms A versus C and (b) arms A versus B versus C (number at risk every 6 months with the number of failure events in
parentheses, after the time in which the number at risk was calculated).
HR, hazard ratio; RMST, restricted mean survival time.
Chemotherapy with placebo





















0 12 24 36 48 60 72 84 96
Time from randomisation to first subsequent treatment (months)
Figure 3. Time from randomisation to first subsequent treatment.
KaplaneMeier plot of the time from randomisation to patients' first subsequent treatment in months.
J. A. Ledermann et al. ESMO Openconcentrating on the toxicity events occurring after 12
months, we observed an increased incidence of the four
most common side-effects in patients taking cediranib.
Grade 3 fatigue occurred in 5% of patients (one patient) in
arm A but in 14% (six patients) in arm C. Grade 2 diarrhoea
was reported by 14% (three) of patients in arm A but by
50% (21 patients) in arm C. Grade 3 diarrhoea was alsomore common in patients on cediranib compared with
placebo, with 5% (one patient) in arm A versus 24% (10
patients) in arm C. Hypertension generally was more com-
mon; at grade 2.18% (four patients) versus 38% (16 pa-
tients) and grade 3.5% (1 patient) versus 10% (4 patients).
Grade 2 nausea was less common in arm A (four patients,
18%) than arm C (11 patients, 26%). This slight increase was
Table 1. Patients' time on treatment
Arm A (118) Arm B (174) Arm C (164)
On treatment >12 months 22 (19%) 31 (18%) 42 (26%)
On treatment >18 months 6 (5%) 13 (7%) 18 (11%)
On treatment >24 months 3 (3%) 4 (2%) 5 (3%)
On treatment >48 months 0 0 1 (<1%)
Median time on treatment 8.2 months 8.2 months 7.6 months
Maximum time on treatment 3.0 years 3.3 years 5.4 years
ESMO Open J. A. Ledermann et al.also mirrored in grade 3 nausea with 5% (1 patient) versus
10% (four) for patients on cediranib.
The only incidents of grade 4 or above were experienced
by <5% of patients; these were one grade 4 thrombosis and
one intra-operative injury, both in arm A.
Of the 26% (42/164) of patients in arm C who were on
trial drug at 1 year, 12% (5/42) stopped due to toxicity
rather than progression.DISCUSSION
We report the final survival analysis of women receiving
platinum-based chemotherapy with or without placebo-
controlled concurrent or concurrent/maintenance cediranib
for platinum-sensitive ovarian cancer treated at first relapse.
Although the primary analysis of ICON6 showed a significant
improvement in PFS with cediranib, this did not lead to a
statistically significant survival benefit. This interim com-
parison of cediranib with chemotherapy and as maintenance
reported a 5.3-month median difference in OS. Cediranib or
placebo was taken for a median of 8.3 (95% CI: 7.5-9.2)
months in Arm B and 8.5 (95% CI: 6.4-9.8) in arm C.16 In this
update we observed a median OS of 27.3 months (95% CI:
24.8-33.0) in arm C and 19.9 months (95% CI: 17.4-26.5) in
arm A and HR of 0.86 (95% CI 0.67-1.11). Several factors
need to be taken into consideration when interpreting these
results. Firstly, the trial was initially planned as a large
randomised trial with OS as the primary outcome. ICON6
became a much smaller study due to a restriction of the
supply of the drug resulting in implementation of PFS as the
primary endpoint. Demonstrating an OS advantage in a small
trial where 90% of patients have post-progression treatment
and a median post-progression survival of 14.4 months is
very unlikely indeed. Secondly, interpretation of the HR and
comparisons of median outcome intervals are less reliable in
situations where there is non-proportionality of the survival
curves. Consequently we have presented restricted median
survival times, showing an increased time until death over a
period of 6 years by a mean of 4.8 (95% CI: 0.09 to 9.74)
months over placebo, from 29.5 to 34.3 months.
Before the definitive OS analysis reported here, a second
interim OS analysis occurred following a request for an
update from the Committee for Medicinal Products for
Human Use (CHMP) at the EMA in November 2014. The
updated analysis for the EMA took place after 74% of
deaths had occurred with a data cut-off of 1 November
2014. The HR at this point in time was 0.84 (95% CI: 0.63-
1.11).24 In preparation for this, three processes were put in
place to refine the data, using the same data cut-off. These
were source data verification, quality checking of data entry,
and blinded independent central review of scans. All had
only a limited impact on the original reported PFS results.30
The company ultimately withdrew their application on 9
September 2016 (13 months later).31
The clinical behaviour of the vascular targeting drug,
cediranib, may be similar to that of other anti-angiogenic
drugs, notably bevacizumab, which when given with
chemotherapy and then as maintenance demonstratedimprovements in PFS without significant OS gains in first-
line or recurrent ovarian cancer treatment.3,4,6,7 Neverthe-
less, such improvements in PFS are considered clinically
meaningful and bevacizumab is licensed for use in first-line
therapy and treatment of recurrent ovarian cancer. In
recurrent ovarian cancer the mature survival analysis in the
OCEANS trial with bevacizumab and chemotherapy has
shown no separation of the treatment and control arms
when reported with >70% deaths.32,33 In the OCEANS trial
there was a 1.7-month median OS difference between
bevacizumab and placebo.32 A larger difference in median
OS of 5.9 months was seen in GOG-0213 in which bev-
acizumab was added to carboplatin and paclitaxel. The
analysis of GOG-0213 was carried out when 62% of patients
had died and the median OS was 42.2 months (95% CI 37.7-
46.2) versus 37.3 months (32.6-39.7) in the chemotherapy
group (HR 0.829; 95% CI 0.683-1.005; P ¼ 0.056).7 However,
for cediranib, with 90% deaths, the analysis shows that
there is an increase of 7.4 months in the median OS and 4.8
months in the RMST over 6 years. At 18 months, 6% more
patients were on cediranib (11%) than on placebo (5%) as
shown in Table 1.
The OS of patients in the ICON6 placebo arm was 19.9
months. This is lower than other comparable trials using
platinum-based combination therapy for recurrent ovarian
cancer. In the OCEANS trial the median OS for the placebo
arm was 35.2 months and in the CALYPSO trial it was 30.7
months and 33.0 months in the chemotherapy arms with
carboplatin and either liposomal doxorubicin or pacli-
taxel.4,21,34 However, a recent analysis of survival of 4739
patients following relapse from randomised first-line phase
III trials through the GOG group showed a median survival
of 21.4 months and a median of 25.4 months when the
most recent trial GOG-0218 is included, suggesting patient
selection may have an influence on outcome.35 We
considered whether the lower median survival in ICON6
could be due to (i) a short time to progression, (ii) a reduced
post-progression survival or (iii) differences in the start of
relapse therapy from the time of diagnosis. The PFS in arm
A (placebo) was 8.4 months. It was 10.4, 11.3 and 9.4
months in GOG-0213, OCEANS and CALYPSO, respectively.
Ninety per cent of patients participating in ICON6 un-
derwent third-line treatment; a similar percentage of post-
progression treatments to that reported in the OCEANS trial
(88.8% and 91.3% patients on the bevacizumab and placebo
arms respectively, and also in the CALYPSO trial34). Post-
hoc, estimating the overall survival in ICON6 from the
date of histological diagnosis, the median OS was 43.3 and
J. A. Ledermann et al. ESMO Open51.3 months for control and cediranib patients (arms A and
C, see Supplementary Material, available at https://doi.
org/10.1016/j.esmoop.2020.100043), respectively, resem-
bling the differences seen with placebo or bevacizumab in
GOG-0218, which were 41.1 and 43.4 months, respec-
tively.33 The ICON6 trial was conducted, like the OCEANS
and GOG-0213 trials, before BRCA testing was carried out
and the use of PARP inhibitors became widespread. Thus,
the outcome of patients enrolled in the ICON6 trial was
broadly similar to a cross-section of GOG-led trials in
ovarian cancer.35
Whilst OS remains the most powerful endpoint in
evaluating a new anti-cancer therapy, there is increasing
recognition that drugs that demonstrate improvements in
PFS and other clinically relevant endpoints can be useful
additions to the therapeutic options available to patients
even in the absence of an OS benefit. In this regard, TFST is
increasingly recognised as a useful endpoint.36 This is
particularly the case for maintenance drugs which by
definition are intended to maintain a stabilised disease
state, postponing introduction of a further chemotherapy
regimen. For cediranib the difference in the median time
from randomisation to the start of a further line
of treatment or death was 1.7 months, from 11.5 to
13.2 months.
All of the published trials of oral VEGFR inhibitors in
ovarian cancer have shown a benefit in PFS, yet none has
been licensed for treatment of recurrent ovarian can-
cer.37,38 However, the positive PFS results from the ICON6
trial have led to a resumption in the manufacture of the
drug and further trials in recurrent ovarian cancer. Different
approaches are being studied by NRG Oncology (USA) and
the NCRI Group (UK). Initial studies suggested a synergy
combining cediranib with olaparib, a PARP inhibitor,39 and it
has more recently been shown that cediranib supresses the
DNA homologous recombination repair pathway making
tumours more sensitive to the PARP inhibitor.40 The US
National Cancer Institute (NCI) have tested the combination
of cediranib and olaparib in a randomised trial, comparing it
to olaparib alone, or intravenous platinum-based chemo-
therapy in recurrent ovarian cancer (NRG-GY004,
NCT02446600). The results recently reported showed that
adding cediranib to olaparib improves anti-tumour activity,
but the combination is not superior to chemotherapy.41 The
ICON group is conducting a trial of maintenance cediranib
and olaparib, compared with olaparib alone after platinum-
based chemotherapy (ICON9, NCT03278717).
Early management of toxicity is important if patients are
to remain on the drug for a prolonged period. Even so, after
12 months of therapy there was a higher incidence of fa-
tigue, diarrhoea and hypertension compared with the pla-
cebo so that careful monitoring of patients is required. Of
the 26% (42/164) of patients in arm C who were on trial
drug for 1 year only, 12% (5/42) stopped treatment due to
toxicity. However, in spite of these toxicities there was no
detrimental effect on quality of life at 1 year.42 In conclu-
sion, the non-significant improvement in survival and sig-
nificant PFS benefit seen with cediranib in ICON6 supportfurther research with this drug in the treatment of recur-
rent ovarian cancer.ACKNOWLEDGEMENTS
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